Plasma Supply Falling Behind Demand: Kristopher Jonas Sounds the Alarm
Kristopher Jonas, CEO/President of Proesis Biologics, posted on LinkedIn:
”You know what’s scary?
The growing gap between how much plasma-derived medicine the world needs and how much plasma we’re actually collecting.
Global demand for immunoglobulins (IG) continues to climb 6–8% each year. And that’s not even factoring in underutilization in low to middle-income countries.
Fractionators are bringing new manufacturing capacity online across the U.S. and Europe.
But all that capacity still depends on one thing – human plasma – and the supply side isn’t keeping pace.
That’s where independent collectors come in.
We’re the flexible link in the chain, able to expand quickly, reach new donor communities, and help ensure the growing global infrastructure doesn’t sit idle waiting for plasma.
Not spooky. Just real.
And it’s why what we’re building at Proesis Bio matters.”
Keep up with Hemostasis Today.
-
Feb 23, 2026, 15:59Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update
-
Feb 23, 2026, 15:54Alan Nurden: From Early Discoveries to New Therapeutic Advances in von Willebrand Disease
-
Feb 23, 2026, 15:52Gevorg Tamamyan: Albania’s Vision for the Future of Pediatric Oncology
-
Feb 23, 2026, 15:36Simon Senanu: The Peripheral Blood Smear as an Essential Diagnostic Tool in Modern Medicine
-
Feb 23, 2026, 15:32Cheng-Hock Toh: The Paradox of Hematology
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1